Loading...

JANX JANUX THERAPEUTICS INC Management Changes 8-K Filing

JNX

JNX

JANUX THERAPEUTICS INC

(JANX)

2026 8-K

Management Change

Annual Meeting Results

Financial Results Released

Board Reorganization

Financial Results Announcement

Collaboration Agreement

Financial Results Report

Management Change

Financial Statements

Financial Statements

Financial Results

Public Offering

Clinical Data Update

Financial Results

Financial Results Announcement

Departure of Directors and ...

Financial Results Announcement

Financial Results Announcement

Public Offering

Suspension of Prospectus Su...

Capital Resources and Inter...

Earnings Reports

Financial Results Announcement

Equity Offerings

Results of Operations and F...

Resignation of CMO

Delisting Notice

Equity Offering

Financial Results Announcement

Departure of Directors

Financial Results Announcement

External Links:

On April 28, 2026, Janux Therapeutics, Inc. reclassified Eric Dobmeier from Class III to Class II director to balance board membership terms, with no disruption in his role or compensation.

AI Assistant

JANUX THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.